-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186

Benzinga·08/10/2026 09:53:16
Listen to the news
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Buy and raises the price target from $110 to $186.